Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Kessler

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Plos One|August 10, 2017
Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancerLars Henning Schmidt, Caroline Brand, Janine Stucke-Ring, et al.
Journal of Cancer Research and Clinical Oncology|January 20, 2026
Undifferentiated pleomorphic sarcoma of bone (UPSB) treated in the German-speaking countries. A report of 132 unselected patients from the Cooperative Osteosarcoma Study Group (COSS)Stefan S Bielack, Dimosthenis Andreou, Daniel Baumhoer, et al.
Plos One|June 13, 2017
Potential therapeutic impact of CD13 expression in non-small cell lung cancerLars Henning Schmidt, Caroline Brand, Janine Stucke-Ring, et al.
Annals of Hematology|March 28, 2013
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one centerJan-Henrik Mikesch, Mareike Kuhlmann, Angela Demant, et al.
European Journal of Haematology|March 29, 2017
Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid cell granulomatosis: A case report and review of the literatureArik Bernard Schulze, Britta Heptner, Torsten Kessler, et al.
Oncotarget|October 15, 2016
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarctionJanine Stucke-Ring, Julian Ronnacker, Caroline Brand, et al.
Cancer Immunology Research|February 13, 2015
Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantationChristoph Schliemann, Katrin L Gutbrodt, Andrea Kerkhoff, et al.
Translational Oncology|August 21, 2018
Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue SarcomaTorsten Kessler, Ariane Baumeier, Caroline Brand, et al.
Annals of Hematology|March 24, 2019
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, et al.
Blood Neoplasia|January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Plos One|August 10, 2017
Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancerLars Henning Schmidt, Caroline Brand, Janine Stucke-Ring, et al.
Journal of Cancer Research and Clinical Oncology|January 20, 2026
Undifferentiated pleomorphic sarcoma of bone (UPSB) treated in the German-speaking countries. A report of 132 unselected patients from the Cooperative Osteosarcoma Study Group (COSS)Stefan S Bielack, Dimosthenis Andreou, Daniel Baumhoer, et al.
Plos One|June 13, 2017
Potential therapeutic impact of CD13 expression in non-small cell lung cancerLars Henning Schmidt, Caroline Brand, Janine Stucke-Ring, et al.
Annals of Hematology|March 28, 2013
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one centerJan-Henrik Mikesch, Mareike Kuhlmann, Angela Demant, et al.
European Journal of Haematology|March 29, 2017
Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid cell granulomatosis: A case report and review of the literatureArik Bernard Schulze, Britta Heptner, Torsten Kessler, et al.
Oncotarget|October 15, 2016
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarctionJanine Stucke-Ring, Julian Ronnacker, Caroline Brand, et al.
Cancer Immunology Research|February 13, 2015
Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantationChristoph Schliemann, Katrin L Gutbrodt, Andrea Kerkhoff, et al.
Translational Oncology|August 21, 2018
Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue SarcomaTorsten Kessler, Ariane Baumeier, Caroline Brand, et al.
Annals of Hematology|March 24, 2019
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, et al.
Blood Neoplasia|January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Pageof 8